Clinical Trials
18 trialsNCT06717347 2026-05-22
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06091865 2026-05-15
OLYMPIA-3
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT05018520 2026-05-11
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
Ruijin Hospital
Phase 3 Recruiting
NCT01804686 2026-05-08
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT04094311 2026-04-20
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT07409428 2026-04-01
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Recruiting
NCT07493109 2026-03-25
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
The First Hospital of Jilin University
Phase 3 Recruiting
NCT07188558 2026-03-04
PiNACLE-H2H
Lyell Immunopharma, Inc.
Phase 3 Recruiting
NCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT06929624 2025-11-18
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT07011056 2025-09-19
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3 Recruiting
NCT06792253 2025-01-24
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 3 Recruiting
NCT04332822 2024-09-19
POLAR BEAR
Nordic Lymphoma Group
Phase 3 Recruiting
NCT06522555 2024-08-05
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Ruijin Hospital
Phase 3 Recruiting
NCT05820841 2023-08-31
ARCHED
Universität des Saarlandes
Phase 3 Recruiting
NCT05351346 2023-03-24
Genotype-guided Treatment in DLBCL
Ruijin Hospital
Phase 3 Recruiting
NCT04442412 2022-08-26
FIL_PREVID
Fondazione Italiana Linfomi - ETS
Phase 3 Recruiting
NCT04670029 2021-10-08
PHARAOM
Weprom
Phase 3 Recruiting